These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 31139863)

  • 1. Skeletal muscle miR-34a/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis.
    Simão AL; Afonso MB; Rodrigues PM; Gama-Carvalho M; Machado MV; Cortez-Pinto H; Rodrigues CMP; Castro RE
    J Mol Med (Berl); 2019 Aug; 97(8):1113-1126. PubMed ID: 31139863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
    Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
    J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
    Long JK; Dai W; Zheng YW; Zhao SP
    Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload.
    Wang L; Sun M; Cao Y; Ma L; Shen Y; Velikanova AA; Li X; Sun C; Zhao Y
    Arch Biochem Biophys; 2020 Nov; 695():108642. PubMed ID: 33098868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patchouli alcohol ameliorates skeletal muscle insulin resistance and NAFLD via AMPK/SIRT1-mediated suppression of inflammation.
    Pyun DH; Kim TJ; Park SY; Lee HJ; Abd El-Aty AM; Jeong JH; Jung TW
    Mol Cell Endocrinol; 2021 Dec; 538():111464. PubMed ID: 34601002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease.
    Shan W; Gao L; Zeng W; Hu Y; Wang G; Li M; Zhou J; Ma X; Tian X; Yao J
    Cell Death Dis; 2015 Jul; 6(7):e1833. PubMed ID: 26203862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of mitochondria-targeted esculetin in the improvement of NAFLD-NASH via modulating AMPK-SIRT1 axis.
    Singuru G; Pulipaka S; Shaikh A; Balaji Andugulapati S; Thennati R; Kotamraju S
    Int Immunopharmacol; 2023 Nov; 124(Pt B):111070. PubMed ID: 37862737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-181b regulates steatosis in nonalcoholic fatty liver disease via targeting SIRT1.
    Wang Y; Zhu K; Yu W; Wang H; Liu L; Wu Q; Li S; Guo J
    Biochem Biophys Res Commun; 2017 Nov; 493(1):227-232. PubMed ID: 28899784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel role of CRTC2 in promoting nonalcoholic fatty liver disease.
    Han HS; Kim SG; Kim YS; Jang SH; Kwon Y; Choi D; Huh T; Moon E; Ahn E; Seong JK; Kweon HS; Hwang GS; Lee DH; Cho KW; Koo SH
    Mol Metab; 2022 Jan; 55():101402. PubMed ID: 34838715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-34a regulates mitochondrial content and fat ectopic deposition induced by resistin through the AMPK/PPARα pathway in HepG2 cells.
    Wen F; An C; Wu X; Yang Y; Xu J; Liu Y; Wang C; Nie L; Fang H; Yang Z
    Int J Biochem Cell Biol; 2018 Jan; 94():133-145. PubMed ID: 29197627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease.
    Ding J; Li M; Wan X; Jin X; Chen S; Yu C; Li Y
    Sci Rep; 2015 Sep; 5():13729. PubMed ID: 26330104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA-141 is associated with hepatic steatosis by downregulating the sirtuin1/AMP-activated protein kinase pathway in hepatocytes.
    Yousefi Z; Nourbakhsh M; Abdolvahabi Z; Ghorbanhosseini SS; Hesari Z; Yarahmadi S; Ezzati-Mobasser S; Seiri P; Borji M; Meshkani R; Malek M
    J Cell Physiol; 2020 Feb; 235(2):880-890. PubMed ID: 31256424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway.
    Yao H; Tao X; Xu L; Qi Y; Yin L; Han X; Xu Y; Zheng L; Peng J
    Pharmacol Res; 2018 May; 131():51-60. PubMed ID: 29574225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melatonin Effects on Non-Alcoholic Fatty Liver Disease Are Related to MicroRNA-34a-5p/Sirt1 Axis and Autophagy.
    Stacchiotti A; Grossi I; García-Gómez R; Patel GA; Salvi A; Lavazza A; De Petro G; Monsalve M; Rezzani R
    Cells; 2019 Sep; 8(9):. PubMed ID: 31500354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligochitosan-based nanovesicles for nonalcoholic fatty liver disease treatment via the FXR/miR-34a/SIRT1 regulatory loop.
    Kong M; Peng Y; Qiu L
    Acta Biomater; 2023 Jul; 164():435-446. PubMed ID: 37040811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D Ameliorates Fat Accumulation with AMPK/SIRT1 Activity in C2C12 Skeletal Muscle Cells.
    Chang E; Kim Y
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31744213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-29a Modulates GSK3β/SIRT1-Linked Mitochondrial Proteostatic Stress to Ameliorate Mouse Non-Alcoholic Steatohepatitis.
    Yang YL; Wang PW; Wang FS; Lin HY; Huang YH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease.
    Xu Y; Zhu Y; Hu S; Pan X; Bawa FC; Wang HH; Wang DQ; Yin L; Zhang Y
    Mol Metab; 2021 Sep; 51():101244. PubMed ID: 33930596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C1q/tumor necrosis factor-related protein-6 attenuates TNF-α-induced apoptosis in salivary acinar cells via AMPK/SIRT1-modulated miR-34a-5p expression.
    Qu LH; Hong X; Zhang Y; Cong X; Xiang RL; Mei M; Su JZ; Wu LL; Yu GY
    J Cell Physiol; 2021 Aug; 236(8):5785-5800. PubMed ID: 33400820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.